Stocks / NASDAQ / Tango Therapeutics Inc.

Tango Therapeutics Inc.

Our Opinion

Tango Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“This first step allows us to identify tumor suppressor genes linked to immune evasion. For the second step, we repeat the in vivo CRISPR screen in animals with an intact immune system looking for potential drug targets that reverse the immune evasion effects of the tumor suppressor gene deletion.” (Page 89) Read the full document

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Company Website: